NLRC5 and neoplasm: Our ongoing studies aim to see whether restoration of NLRC5 and/or use of dsRNA analog such as poly I:C can actually enhance antigen presentation, T cell-mediated tumor cell killing, and sensitivity to ICB in HNSCC models with deficient IFN/STAT1 signaling.